An official website of the United States government
Home
Name
ECOG
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for ECOG
Name
Alternate Names
496
5-Azacitidine
5-Azacytidine
Antibiotic U-18
Azacitidine
Azacytidine
Ladakamycin
Abbreviations
5-AC
5-AZA
5-AZAC
5-AZCR
AZA-CR
AZC
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
102816
Primary Site
Myelodysplastic syndromes
Histology
Myelomonocytic leukemia
Remarks
May 27, 2022 FDA approved Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.
Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.
Clinical trials for MDS and AML. Antineoplastic agent; reduction in size or spread of neoplasm; improvement in hematologic parameters; bone marrow aspirate; antimetabloite; also differentiation inducing agent.
Coding
This drug should be coded
Name
Alternate Names
Gemcitabine Hydrochloride
Gemzar
LY 188011
LY-188011
LY188011 hydrochloride
Gemcitabine HCL
Abbreviations
None
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
613327
Primary Site
Histology
None
Remarks
FDA approved for breast. ovarian, pancreas, NSC lung
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
Gemcitabine HCL is given intravesically as treatment for bladder tumors. Code as chemotherapy.
Coding
This drug should be coded
